Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Exelixis, BMS To Co-Develop Cancer Drug | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Exelixis, BMS To Co-Develop Cancer Drug

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Bristol-Myers Squibb has exercised its option to develop and commercialize Exelixis’ compound XL139. Exelixis will receive a $20 million milestone payment and has exercised its option to co-develop and co-commercialize the drug in the U.S. BMS will lead all global activities and the parties will co-develop and co-commercialize XL139 in the U.S. and split those profits. Exelixis will be entitled to receive royalties on product sales outside of the U.S.
   
XL139 is a small molecule inhibitor of the hedgehog pathway. Hedgehog signaling is deregulated in a variety of cancers and the pathway is a promising target for novel cancer therapies.
   
“I am pleased that Bristol-Myers Squibb shares our enthusiasm for the potential of hedgehog pathway modulators and of XL139 in particular. This is an exciting pathway with therapeutic potential for a number of solid tumor types,” said George A. Scangos, Ph.D., president and chief executive officer of Exelixis. “Bristol-Myers Squibb has substantial expertise in commercializing innovative cancer therapies, and we are excited to have another opportunity to work with and learn from our Bristol-Myers Squibb colleagues. We expect that Bristol-Myers Squibb’s resources will help speed the development of this novel compound designed to inhibit an important cancer-related pathway. This will enable us to deploy our internal resources on our proprietary assets.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters